Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04677244
Other study ID # EUS-CTC-IPC 2019-056
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 11, 2021
Est. completion date November 1, 2025

Study information

Verified date April 2024
Source Institut Paoli-Calmettes
Contact Dominique GENRE, MD
Phone +33491223778
Email drci.up@ipc.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this work is to evaluate the impact of endoscopic procedures on the circulating tumoral cells level in order to evaluate the potential effects of an endoscopic procedure in the management of pancreatic tumors.


Description:

The study will include 42 evaluable patients suspected of having pancreatic cancer and for whom an echo-endoscopic biopsy (EUS-FNA) and/or biliary drainage is planned. In these patients, a 6 ml blood sample will be taken from the portal vein before and after the echo-endoscopic biopsy of the pancreatic mass to determine: - the level of circulating tumor cells (CTC) per milliliter of blood, - cytological characteristics of CTCs (isolated, clustered, giant, and clustered including other cell types). A peripheral blood sample will also be taken to evaluate peripheral CTC levels and cytological characteristics before and after biopsy, as well as one month after biopsy. Patients will be evaluated every 6 months as part of their follow-up to assess the progression of their pathology and morbidity.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date November 1, 2025
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria: - Men and women aged 40-85 years old; - BMI< 30 kg/m2; - Patients suspected of having pancreatic cancer for whom an ultrasound endoscopic biopsy and/or biliary drainage is planned; - Affiliation to, or beneficiary of, a social security scheme. Exclusion Criteria: - Woman who is pregnant or likely to become pregnant (without effective contraception) or breastfeeding ; - Person in an emergency situation, person of full age subject to a legal protection measure, or unable to express consent; - Biliary drainage or attempt at prior biliary drainage outside the center ; - Preliminary oncological treatment for pancreatic pathology covered by the study; - Clinical and/or image-visible (CT/MRI) carcinosis ; - Ascites visible on imaging (CT/MRI) ; - Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons; - Contraindications to an endoscopic procedure.

Study Design


Intervention

Procedure:
Blood sample in portal vein
A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.

Locations

Country Name City State
France Institut Paoli Calmettes Marseille

Sponsors (1)

Lead Sponsor Collaborator
Institut Paoli-Calmettes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedure impact Rate of patients with a CTC increase > 4 cells/ml in the portal system after the endoscopic procedure 5 minutes after procedure
See also
  Status Clinical Trial Phase
Terminated NCT02902484 - Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT04008537 - Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT03659292 - Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy N/A
Completed NCT03150615 - Enteral Nutrition After Pancreaticoduodenectomy N/A
Recruiting NCT02682394 - Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas N/A
Recruiting NCT05566743 - A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas Phase 2
Not yet recruiting NCT04049461 - Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Active, not recruiting NCT04128332 - Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer N/A
Recruiting NCT03536793 - Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Recruiting NCT02311439 - Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Phase 2/Phase 3
Completed NCT02296736 - The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
Withdrawn NCT04123574 - A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Early Phase 1
Not yet recruiting NCT03278015 - Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT02905578 - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Phase 2
Completed NCT01446458 - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Phase 1
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06148298 - Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
Terminated NCT03451773 - M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas Phase 1/Phase 2